Drug-Eluting Stents Will Pay Their Own Way According To SIRIUS Cost Study

The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial